Curis
CRIS
$14.47
Share price
-0.34%
Change (1 day)
1,731.65%
Change (1 year)
Categories
Curis (CRIS) - P/B ratio
P/B ratio as of April 2024 : 4.40
According to Curis's latest financial reports the company has a price-to-book ratio of 4.40.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Curis - P/B ratio (from 2001 to 2023)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | 3.82 | 235.45% |
| 2022-12-31 | 1.14 | -76.31% |
| 2021-12-31 | 4.81 | -13.15% |
| 2020-12-31 | 5.54 | -432.17% |
| 2019-12-31 | -1.67 | -67.24% |
| 2018-12-31 | -5.09 | -206.34% |
| 2017-12-31 | 4.78 | -67.66% |
| 2016-12-31 | 14.8 | 154.21% |
| 2015-12-31 | 5.82 | 34.29% |
| 2014-12-31 | 4.33 | -19.16% |
| 2013-12-31 | 5.36 | -33.08% |
| 2012-12-31 | 8.01 | -10.89% |
| 2011-12-31 | 8.99 | 169.02% |
| 2010-12-31 | 3.34 | -49.52% |
| 2009-12-31 | 6.62 | 417.62% |
| 2008-12-31 | 1.28 | -3.35% |
| 2007-12-31 | 1.32 | -23.6% |
| 2006-12-31 | 1.73 | -62.54% |
| 2005-12-31 | 4.62 | -9.97% |
| 2004-12-31 | 5.13 | 9.32% |
| 2003-12-31 | 4.70 | 166.31% |
| 2002-12-31 | 1.76 |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 1.61 | -63.42% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 3.09 | -29.91% | 🇺🇸 USA |
 Spectrum Pharmaceuticals
SPPI | 7.89 | 79.17% | 🇺🇸 USA |
 Exelixis EXEL | 3.09 | -29.87% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | 5.56 | 26.24% | 🇺🇸 USA |
 Cel-Sci
CVM | 6.10 | 38.62% | 🇺🇸 USA |
 Emergent BioSolutions
EBS | 0.1549 | -96.48% | 🇺🇸 USA |